Optimizing dose-dense regimens for early-stage breast cancer

Nature Reviews Clinical Oncology

Volumn 7, Issue 12, 2010, Pages 678-679

  Morris, Patrick G ^a   Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERIBULIN; LAPATINIB; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; TRASTUZUMAB;

BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; EARLY CANCER; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SHORT SURVEY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MASTECTOMY; MULTICENTER STUDIES AS TOPIC; NEOPLASM STAGING; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 78649682851     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.188     Document Type: Short Survey

References (10)

1. Bonadonna, G. et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294, 405-410 (1976).
2. Early Breast Cancer Trialists' Collaborative Group (eBCTCG). effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
3. De Laurentiis, M. et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26, 44-53 (2008).
4. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 48; l7067-7071 (1988).
5. Citron, M. L. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439 (2003)
6. Moebus, v. et al. intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase iii study. J. Clin. Oncol. 28, 2874-2880 (2010).
7. Budman, D. R. et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J. Natl Cancer Inst. 90, 1205-1211 (1998).
8. Sparano, J. A. et al. weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 358, 1663-1671 (2008).
9. Morris, P. G. et al. Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J. Clin. Oncol. 27, 6117-6123 (2009).
10. Dang, C. et al. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HeR2/neu-overexpressed/ amplified breast cancer is not feasible because of excessive diarrhea. J. Clin. Oncol. 28, 2982-2988 (2010).